Home > Drugs A – Z > Lomustine (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Lomustine (By mouth)

Treats Hodgkin's disease, brain tumors, and other kinds of cancers, often in combination with other medicines. Also called CCNU. This medicine is an alkylating agent.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Lomustine is used alone or in combination with other medicines to treat brain tumors, Hodgkin's disease, and other kinds of cancer. This medicine belongs to the group of medicines known as alkylating agents. Lomustine interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal body cells may also be affected by lomustine, other effects may occur. Some of… Read more
Brand names include
Ceenu
Drug classes About this
Antineoplastic Agent

What works? Research summarized

Evidence reviews

Hydroxyurea for the Treatment of Sickle Cell Disease

To synthesize the published literature on the efficacy, effectiveness, and toxicity of hydroxyurea (HU) when used for treatment of sickle cell disease (SCD); and to review the evidence regarding barriers to its use.

Life-threatening dermatologic adverse events in oncology

The incidences of life-threatening toxicities such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are inconsistently reported. The potential association of anticancer agents with SJS or TEN has not been systematically investigated. We searched the literature (Ovid: 1950 to June 2013 and PubMed: 1948 to June 2013) using terms for SJS/TEN and anticancer therapies. Primary case reports, case series, and clinical trials were included. In addition, MedWatch, the Food and Drug Administration Adverse Event Reporting System (FAERS), was searched (1968 to August 2012) for SJS/TEN reports associated with anticancer therapies. Proportional reporting ratios (PRR>2, N>3), empirical Bayes geometric mean (EBGM>2, N>3), and lower 95% confidence interval (EBGM0.05>2) were used as thresholds to constitute a signal of association between SJS/TEN and anticancer drugs. There were 46 SJS and 37 TEN cases associated with 18 and 22 anticancer drugs in the literature, respectively. Among cases in the FAERS, significant signals were associated with SJS for bendamustine and with TEN for bendamustine, busulfan, chlorambucil, fludarabine, lomustine, and procarbazine. Several drugs reported in the published literature to be associated with SJS/TEN were not found to have significant signals in FAERS. Proactive pharmacovigilance to detect and define safety signals serves to aid oncology practitioners in the recognition of possible, yet uncommon, serious, and/or life-threatening skin reactions.

A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly

This review concluded that all-trans retinoic acid or lomustine might be an effective addition but most induction regimens for acute myeloid leukaemia treatment had similar efficacy in elderly patients. The authors cautioned about the extent of the reliance on indirect comparisons. Potential selection biases and uncertain quality of the included trials may reduce the reliability of the conclusions.

See all (5)

Summaries for consumers

Does giving chemotherapy, radiotherapy or both improve survival in people with rare (anaplastic oligodendrogliomas and oligoastrocytomas) brain tumours?

Traditionally, the standard of care for people with rare anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (brain tumours) has been surgery followed by radiotherapy. However, the benefit of adjuvant (post‐surgery) chemotherapy and radiotherapy is still unclear. In addition, the value of chromosome markers is also under investigation.

Sexuality and Reproductive Issues (PDQ®): Patient Version

Expert-reviewed information summary about factors that may affect sexual functioning in people with cancer. Fertility issues related to cancer treatment are also discussed.

Late Effects of Treatment for Childhood Cancer (PDQ®): Patient Version

Expert-reviewed information summary about the health problems that continue or appear after cancer treatment has ended.

PubMed Health Blog...

read all...